Assessing risk to benefit ratio in antiepileptic drug therapy.
about
Seletracetam (UCB 44212)Supportive management of patients with brain tumors.Age and sex dependent changes in liver gene expression during the life cycle of the rat.Clinical pharmacology and therapeutic use of the new antiepileptic drugs.What can we learn from clinical trials of anticonvulsant drugs in epilepsy?The use of antiepileptic drugs--principles and practice.Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients.Emerging drugs for partial-onset epilepsy: a review of brivaracetamEvaluation of self-reported medication adherence and its associated factors among epilepsy patients in Hospital Kuala Lumpur.Antiepileptic drug-related adverse reactions and factors influencing these reactions.Sex and age differences in the expression of liver microRNAs during the life span of F344 rats.The long-term safety of antiepileptic drugs.Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review.Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses.Analysis of drug use in institutionalized individuals with intellectual disability and tube feeding.Efficacy and tolerability of anti-epileptic drugs-an internet study.Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.Effect on epileptogenesis of carbamazepine treatment during the silent period of the pilocarpine model of epilepsy.
P2860
Q28281424-150F86EC-9DD7-4C50-9985-031E13A1498EQ30444752-CDE1135C-569E-4A7E-BE68-17DAF43FAC4EQ33758968-4C2C069D-C2D5-43D5-923F-43BD8F811FB3Q34541736-C9040C80-EA8F-4204-A7A1-5120BDA2173EQ34558531-8C2E6148-AB32-4A90-94DC-E410E090E38FQ35865176-AB6E090B-C3BD-457C-AC31-9F171D3A20CAQ36072406-9E2335B3-7297-4DB0-B365-59FA0038523EQ36891212-ACC8C8C3-793D-4FEB-B530-FBE8DBA9BEDDQ37498042-0A7A333A-B17B-4AC7-ABC3-BD14AA3636FAQ37618493-9D90402E-D973-4515-A9FA-E2B23EEBCA25Q37624573-D307C107-AF8C-4241-8EFD-D7E77D75DB93Q38106856-93CBBED7-F0D6-49E0-867D-C2515BE21CC9Q38219326-C7244EE2-7E92-4CC0-BB13-4317FDF33A0CQ38990303-23C71E79-0D2B-4CA3-A50D-C35A22C53FFFQ39852900-7A542C1D-15D1-47F6-B05D-04DFF067C60DQ40531398-6C84B965-8797-4A07-9829-EF27FF385786Q42095188-B1EC2C43-2DAA-4A61-B6FF-343D71B9162EQ44066405-1CB5E58A-3F43-48C9-A244-27CD61A11A01
P2860
Assessing risk to benefit ratio in antiepileptic drug therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Assessing risk to benefit ratio in antiepileptic drug therapy.
@ast
Assessing risk to benefit ratio in antiepileptic drug therapy.
@en
Assessing risk to benefit ratio in antiepileptic drug therapy.
@nl
type
label
Assessing risk to benefit ratio in antiepileptic drug therapy.
@ast
Assessing risk to benefit ratio in antiepileptic drug therapy.
@en
Assessing risk to benefit ratio in antiepileptic drug therapy.
@nl
prefLabel
Assessing risk to benefit ratio in antiepileptic drug therapy.
@ast
Assessing risk to benefit ratio in antiepileptic drug therapy.
@en
Assessing risk to benefit ratio in antiepileptic drug therapy.
@nl
P2093
P1433
P1476
Assessing risk to benefit ratio in antiepileptic drug therapy.
@en
P2093
P304
P356
10.1016/S0920-1211(00)00124-8
P577
2000-09-01T00:00:00Z